ANN ARBOR, MI / ACCESSWIRE / February 6, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced that it will be hosting a Virtual Investor Day event on Tuesday, February 13, 2024, starting at 3:00 p.m. ET.
The virtual-only webcast event will feature presentations from select members of the management team. The event will provide an overview of Zomedica's portfolio of innovative products, world-class manufacturing facilities, recent business developments, and scientific and information technology capabilities. In addition, key drivers of future growth and commercial execution along with the broader animal health addressable market opportunity and financial position will be discussed.
A live question-and-answer session will follow management's webcast presentation.
Event: Zomedica Virtual Investor Day 2024
Date: Tuesday, February 13, 2024
Time: 3:00 p.m. Eastern Time
Webcast: Zomedica Virtual Investor Day
Full replay of the webcast will be available on Zomedica's website at Events & Presentations | Zomedica Inc.
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company creating diagnostic and therapeutic products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. Zomedica's mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit zomedica.com.
Follow Zomedica
Investor Contact:
Zomedica Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-734-369-2555
| Last Trade: | US$0.04 |
| Daily Volume: | 735,048 |
May 13, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
